[Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab]

Affiliations

• ¹ Pirogov Russian National Research Medical University, Moscow, Russia; Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia.
• ² Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia; City Center of Multiple Sclerosis And Autoimmune Diseases at Hospital #31, Moscow, Russia.
• ³ Burdenko Research Institute of Neurosurgery, Moscow, Russia.
• ⁴ Pirogov Russian National Research Medical University, Moscow, Russia.
• ⁵ Neurology Research Center, Moscow, Russia.
• ⁶ Siberian State Medical University, Tomsk, Russia.
• ⁷ Siberian Regional Hospital #1, Yekaterinburg, Russia.
• ⁸ Novosibirsk State Medical University, Novosibirsk, Russia.
• ⁹ Tyumen State Medical University, Tyumen, Russia.
• ¹⁰ Research Institute - Ochapovsky Regional Hospital #1, Krasnodar, Russia.
• ¹¹ Pavlov St. Petersburg State Medical University, St. Petersburg, Russia.
• ¹² Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia.